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The impact of Connshing’s syndrome -
mild cortisol excess in primary
aldosteronism drives diabetes risk
Felix Beuschlein, Martin Reincke, and
Wiebke Arlt
W
ith great interest, we have read the recent study
by Wu et al. [1]. By taking advantage of the
Taiwan National Health Insurance database,
the authors provide evidence that in patients with primary
aldosteronism, treatment by adrenalectomy (ADX) signifi-
cantly reduced the risk of new-onset diabetes mellitus
(NODM) to the level observed in patients with essential
hypertension. Significantly, patients receiving medical
therapy of primary aldosteronism with mineralocorticoid
receptor antagonist (MRA) had a significantly higher risk
of diabetes than patients with essential hypertension. The
authors suggest some potential explanations for
these disparate results: Although ADX would normalize
aldosterone hypersecretion levels shortly after surgery,
MRA therapy could augment circulating aldosterone serum
levels, which might be associated with deleterious non-
genomic effects of aldosterone. Further explanations
might include low long-term adherence to MRA therapy
and a more pronounced effect on blood pressure control
by ADX.
Although we agree that the proposed mechanisms may
contribute to the observed difference of surgical and
medical therapy on metabolic effects in primary aldoster-
onism patients, wewould like to point out another potential
explanation for this interesting epidemiological obser-
vation. We could recently demonstrate by a mass spec-
trometry-based analysis of the 24-h urine steroid
metabolome in 174 patients with newly diagnosed primary
aldosteronism that a significant proportion had mild glu-
cocorticoid excess concurrently with excess production of
aldosterone [2], a constellation we termed Connshing’s
syndrome. In our cohort, ADX resolved both mineralocor-
ticoid and glucocorticoid excess and a proportion of
around 30% of patients undergoing surgery even had
evidence of postoperative adrenal insufficiency. Intratumor
expression of the cortisol synthesis enzyme CYP11B1 was
significantly associated with the corresponding in-vivo
glucocorticoid excretion. In our patient cohort, several
surrogate parameters of metabolic risk correlated signifi-
cantly with glucocorticoid but not mineralocorticoid
output. We proposed that, although ADX removed both
mineralocorticoid and glucocorticoid excess, patients
treated with MRA might have persistent metabolic risk, as
the glucocorticoid excess remains unopposed.
This hypothesis is also supported by a recent cohort
study in 2533 primary aldosteronism patients [3], published
by the same group as the current report on NODM risk.
That report found an ongoing increase in osteoporotic
fracture risk in women with primary aldosteronism
receiving treatment with MRA, whereas women who
underwent surgical removal of their aldosterone-produc-
ing adrenal adenoma did not have an increased risk
of osteoporosis.
Hypercortisolism, even if mild as in primary aldosteron-
ism patients, is able to increase the risk for osteoporosis [4]
and diabetesmellitus [5], whereas those risks are difficult to
reconcile with aldosterone excess. Therefore, we propose
that the correction of coexisting hypercortisolism by ADX
will be the main reason for the improvement of NODM
observed by Wu et al. [1]. This cannot be achieved by
selective MRA therapy, with persistent adrenal cortisol
excess driving the increased risk of NODM and osteo-
porosis.
Prospective randomized studies would be necessary to
clarify whether patients with primary aldosteronism and
evidence of Connshing’s syndrome should receive
additional glucocorticoid-opposing treatment when treated
medically with MRA to efficiently counteract adverse
metabolic risk.
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